<?xml version="1.0" encoding="UTF-8"?><ns2:project xmlns:ns1="http://gtr.rcuk.ac.uk/gtr/api" xmlns:ns2="http://gtr.rcuk.ac.uk/gtr/api/project" xmlns:ns3="http://gtr.rcuk.ac.uk/gtr/api/fund" xmlns:ns4="http://gtr.rcuk.ac.uk/gtr/api/person" xmlns:ns5="http://gtr.rcuk.ac.uk/gtr/api/project/outcome" xmlns:ns6="http://gtr.rcuk.ac.uk/gtr/api/organisation" ns1:created="2026-06-22T07:57:45Z" ns1:href="http://gtr.ukri.org/gtr/api/projects/C9BD146B-CCCA-4665-AA09-0F7E66962011" ns1:id="C9BD146B-CCCA-4665-AA09-0F7E66962011"><ns1:links><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/organisations/2295C2B1-419F-4515-81E2-AEFEFBDA4901" ns1:rel="LEAD_ORG"/><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/organisations/2295C2B1-419F-4515-81E2-AEFEFBDA4901" ns1:rel="PARTICIPANT_ORG"/><ns1:link ns1:end="2014-08-30T23:00:00Z" ns1:href="http://gtr.ukri.org/gtr/api/funds/88D6923F-D41A-4D0B-857C-5F030BD7A304" ns1:rel="FUND" ns1:start="2010-03-31T23:00:00Z"/></ns1:links><ns2:identifiers><ns2:identifier ns2:type="RCUK">730031</ns2:identifier></ns2:identifiers><ns2:title>Next generation Anti-Microbial Cleaner</ns2:title><ns2:status>Closed</ns2:status><ns2:grantCategory>Legacy RDA Grant for R&amp;D</ns2:grantCategory><ns2:leadFunder>Innovate UK</ns2:leadFunder><ns2:abstractText>Byotrol is a North West based SME focussed on developing and commercialising products
based upon their highly unique, innovative, anti-microbial cleaning solution. Put simply,
when applied to a surface, the solution will not only kill bacteria but will continue to protect
against bacteria hours after its application.
Byotrol wish to develop a second generation solution that can be modified the meet the
challenging environments such a hospitals, the home and mobile treatments while still
retaining the residual and anti-microbial properties. In order to achieve this research will be
done into the modifiable properties of the current solution and different biocide-polymer
combinations experimented with in order to enhance the solutions properties. Solutions for the
healthcare and military environments will then be developed and a pre-production prototype
of a wound dressing incorporating the developed solution produced.
The project is expected to cost &amp;pound;1.5 million pounds, which represents a considerable amount
of money and risk for an SME such as Byotrol. NWDA supported is needed if therefore
requested in order to enable the project to take place. Doing so would ensure the highly
innovative commercial project takes place in the North West and the safeguarding of 3 highly
skilled R&amp;amp;D at Daresbury. It would also allow the North West to take the lead in the next
generation anti-microbial technology that will directly benefit the NHS and MOD.</ns2:abstractText></ns2:project>